News
Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...
Pfizer CEO Albert Bourla said Tuesday he has a "special relationship" with President Trump, cemented during the COVID-19 ...
Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...
Pfizer (PFE) stock is rising after the company reported strong second-quarter earnings and lifted its full-year forecast ...
Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 ...
Pfizer stock rose after the drugmaker posted adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, ...
CEO says pharma executives discussed Trump's call to launch DTC initiatives under his Most Favored Nation policy to lower U.S ...
Pfizer has abanonded yet another GLP-1 drug from its shrinking obesity pipeline, as well as dumping a Clostridium difficile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results